JP2017525738A - 皮膚におけるバリア機能のｕｖ誘導性喪失の処置に使用される局所プテロスチルベン組成物 - Google Patents

皮膚におけるバリア機能のｕｖ誘導性喪失の処置に使用される局所プテロスチルベン組成物 Download PDF

Info

Publication number
JP2017525738A
JP2017525738A JP2017512286A JP2017512286A JP2017525738A JP 2017525738 A JP2017525738 A JP 2017525738A JP 2017512286 A JP2017512286 A JP 2017512286A JP 2017512286 A JP2017512286 A JP 2017512286A JP 2017525738 A JP2017525738 A JP 2017525738A
Authority
JP
Japan
Prior art keywords
skin
pterostilbene
topical
individual
loss
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017512286A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017525738A5 (enExample
Inventor
メイスケンス，　フランク　エル．　ジュニア
フランク エル． ジュニア メイスケンス，
ライアン ダブリュー． デリンガー，
ライアン ダブリュー． デリンガー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
University of California Berkeley
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of JP2017525738A publication Critical patent/JP2017525738A/ja
Publication of JP2017525738A5 publication Critical patent/JP2017525738A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
JP2017512286A 2014-09-04 2015-09-03 皮膚におけるバリア機能のｕｖ誘導性喪失の処置に使用される局所プテロスチルベン組成物 Pending JP2017525738A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462046068P 2014-09-04 2014-09-04
US62/046,068 2014-09-04
PCT/US2015/048422 WO2016036999A1 (en) 2014-09-04 2015-09-03 Topical pterostilbene compositions for use in treating uv-induced loss of barrier function in skin

Publications (2)

Publication Number Publication Date
JP2017525738A true JP2017525738A (ja) 2017-09-07
JP2017525738A5 JP2017525738A5 (enExample) 2018-10-04

Family

ID=55436471

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017512286A Pending JP2017525738A (ja) 2014-09-04 2015-09-03 皮膚におけるバリア機能のｕｖ誘導性喪失の処置に使用される局所プテロスチルベン組成物

Country Status (11)

Country Link
US (1) US9980924B2 (enExample)
EP (1) EP3194032B1 (enExample)
JP (1) JP2017525738A (enExample)
KR (1) KR20170045343A (enExample)
CN (1) CN107106877A (enExample)
AU (1) AU2015311799A1 (enExample)
BR (1) BR112017004304B1 (enExample)
CA (1) CA2959756C (enExample)
MX (1) MX375612B (enExample)
WO (1) WO2016036999A1 (enExample)
ZA (1) ZA201701510B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019055932A (ja) * 2017-09-20 2019-04-11 学校法人同志社 Ｄｊ−１タンパク質産生促進用組成物

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX375612B (es) 2014-09-04 2025-03-06 Univ California Composiciones tópicas de pterostilbeno para utilizarse en el tratamiento de la pérdida inducida por uv de la función de barrera en la piel.
EP3501490B1 (en) * 2016-08-17 2023-08-30 Tomoike Bio Ltd. Composition for external use that includes pterostilbene glycoside
CA3163065A1 (en) 2019-12-30 2021-07-08 George P. Majewski Ppar agonist complex and methods of use
EP4029496A1 (en) * 2021-01-18 2022-07-20 Universitat de València Pterostilbene and silibinin for preventing, ameliorating or reducing radiation-induced diseases

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100240767A1 (en) * 2009-03-23 2010-09-23 Muhammed Majeed Melanogenesis inhibitiuon by 3,5-dimethoxy-4'-hydroxystilbenes and cosmeceutical compositions thereof
JP2010536764A (ja) * 2007-08-13 2010-12-02 イーエルシー マネージメント エルエルシー ヒト皮膚を修復するための化粧的方法および化粧用組成物
JP2013509385A (ja) * 2009-10-30 2013-03-14 グリーン モールキュラー，エス．エル 皮膚の疾患、傷害または損傷の予防および／または処置における使用のためのプテロスチルベン（ｐｔｅｒ）
JP2013075851A (ja) * 2011-09-30 2013-04-25 Fujifilm Corp 皮膚外用剤
WO2013169291A2 (en) * 2012-05-08 2013-11-14 ChromaDex Inc. Method for inducing udp-glucuronosyltransferase activity using pterostilbene

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2820975B1 (fr) 2001-02-21 2004-03-12 Oreal Composition pour application topique comprenant au moins un hydroxystilbene et au moins un polyol pour solubiliser l'hydroxystilbene
US8703161B2 (en) 2007-08-13 2014-04-22 Elc Management, Llc Skin repair compositions comprising circadian gene activators and a synergistic combination of Sirt1 gene activators
US20130296440A1 (en) 2012-05-01 2013-11-07 ChromaDex Inc. Pterostilbene and curcumin combination for treatment of oxidative stress and inflammation
CN103239540B (zh) * 2013-04-03 2014-11-12 广东药学院 一种凉血愈伤方提取物及治疗皮肤烧伤的复方白藜芦醇凉血愈伤油制剂
WO2016037007A1 (en) 2014-09-04 2016-03-10 The Regents Of The University Of California Topical pterostilbene compositions for use in treating uv-induced skin damage and hyperplasia
MX375612B (es) 2014-09-04 2025-03-06 Univ California Composiciones tópicas de pterostilbeno para utilizarse en el tratamiento de la pérdida inducida por uv de la función de barrera en la piel.

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010536764A (ja) * 2007-08-13 2010-12-02 イーエルシー マネージメント エルエルシー ヒト皮膚を修復するための化粧的方法および化粧用組成物
US20100240767A1 (en) * 2009-03-23 2010-09-23 Muhammed Majeed Melanogenesis inhibitiuon by 3,5-dimethoxy-4'-hydroxystilbenes and cosmeceutical compositions thereof
JP2013509385A (ja) * 2009-10-30 2013-03-14 グリーン モールキュラー，エス．エル 皮膚の疾患、傷害または損傷の予防および／または処置における使用のためのプテロスチルベン（ｐｔｅｒ）
JP2013075851A (ja) * 2011-09-30 2013-04-25 Fujifilm Corp 皮膚外用剤
WO2013169291A2 (en) * 2012-05-08 2013-11-14 ChromaDex Inc. Method for inducing udp-glucuronosyltransferase activity using pterostilbene

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CICHOCKI, MICHAL ET AL.: "Pterostilbene is equally potent as resveratrol in inhibiting 12-O-tetradecanoylphorbol-13-acetate ac", MOLECULAR NUTRITION & FOOD RESEARCH, vol. 52, JPN6014040641, 2008, pages 62 - 70, ISSN: 0004223164 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019055932A (ja) * 2017-09-20 2019-04-11 学校法人同志社 Ｄｊ−１タンパク質産生促進用組成物
JP7061766B2 (ja) 2017-09-20 2022-05-02 学校法人同志社 Ｄｊ－１タンパク質産生促進用組成物

Also Published As

Publication number Publication date
US20160067194A1 (en) 2016-03-10
MX2017002818A (es) 2017-08-02
BR112017004304B1 (pt) 2020-12-08
EP3194032B1 (en) 2021-06-23
CA2959756C (en) 2023-02-28
AU2015311799A1 (en) 2017-03-30
BR112017004304A2 (pt) 2017-12-05
EP3194032A4 (en) 2018-05-23
KR20170045343A (ko) 2017-04-26
CN107106877A (zh) 2017-08-29
US9980924B2 (en) 2018-05-29
CA2959756A1 (en) 2016-03-10
WO2016036999A1 (en) 2016-03-10
MX375612B (es) 2025-03-06
EP3194032A1 (en) 2017-07-26
ZA201701510B (en) 2018-11-28

Similar Documents

Publication Publication Date Title
Yaghoobi et al. Vitiligo: a review of the published work
Alam et al. The neurobehavioral changes induced by bilateral rotenone lesion in medial forebrain bundle of rats are reversed by L-DOPA
Amini et al. Nonsurgical innovations in the treatment of nonmelanoma skin cancer
Yarosh et al. Anti-inflammatory activity in skin by biomimetic of Evodia rutaecarpa extract from traditional Chinese medicine
US20120258060A1 (en) Methods for protecting the skin from radiation insults
JP2017525738A (ja) 皮膚におけるバリア機能のｕｖ誘導性喪失の処置に使用される局所プテロスチルベン組成物
Thakur et al. Vitiligo: Translational research and effective therapeutic strategies
US8029770B2 (en) Caffeine salt complexes and methods for using the same in the prevention or treatment of cancer
Reeta et al. Curcumin ameliorates cognitive dysfunction and oxidative damage in phenobarbitone and carbamazepine administered rats
CN117377475B (zh) 治疗与糖尿病性周围神经病变相关的疼痛
IL235449A (en) Method for Identifying ahr Receptor Ligands with Suppressive Medical Activity Fat Excretion and the Ligands
KR20040105706A (ko) 화학적 예방 활성을 나타내는 비스테로이드계 소염제를함유하는 국소 제형
ES2610754T3 (es) Composición que comprende dihidroquercetina, alfa-tocoferol y bisabolol
Hercogová et al. A rational approach to the treatment of vitiligo and other hypomelanoses
Miville-Godbout et al. Plasmalogen precursor mitigates striatal dopamine loss in MPTP mice
JP2021505621A (ja) Ｐｄｅ−４阻害剤の局所軟膏製剤および皮膚状態の治療におけるそれらの使用
US20160067193A1 (en) Topical pterostilbene compositions for use in treating uv-induced skin damage and hyperplasia
Coopman et al. Phototherapy with ultraviolet B
US20230172960A1 (en) Topical capecitabine for the treatment of hyperproliferative skin conditions
HK1241310B (en) Topical pterostilbene compositions for use in treating loss of barrier function in skin in burn injurys
Hartmann et al. Repigmentation of pretibial vitiligo with calcineurin inhibitors under occlusion
Pustišek et al. A review of sunscreens and their adverse reactions
Gianfaldoni et al. Vitiligo repigmentation: what’s new
TW201632182A (zh) 治療皮膚之腫瘤及癌前病理的雷公藤內酯及其衍生物
Zhang et al. The antinociceptive effect and mechanism of action of SY0916

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180824

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180824

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190604

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190903

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191105

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200302

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20201006